1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November

Gilead Sciences is recommended as a strong dividend-paying biotech stock for November. The company delivered solid Q3 2026 results with 7% revenue growth to $8.3 billion, driven by strong HIV product sales (up 18% YoY) and liver disease portfolio performance. Recent FDA approvals including Bixlenvo and Hepcludex, combined with an expanding oncology pipeline, should support future growth. Trading at a reasonable 16.8x forward earnings with a 2% dividend yield and 74.5% payout increase over the past decade, Gilead appears well-positioned for long-term investors.